116 related articles for article (PubMed ID: 15613906)
1. Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial.
Neri B; Cipriani G; Fulignati C; Turrini M; Ponchietti R; Bartoletti R; Della Melina A; Di Cello V; Dominici A; Maleci D; Raugei A; Villari D; Nicita G
Anticancer Drugs; 2005 Jan; 16(1):63-6. PubMed ID: 15613906
[TBL] [Abstract][Full Text] [Related]
2. Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
Neri B; Molinara E; Pantaleo P; Rangan S; Crisci A; Della Melina A; Raugei A; Villari D; Nicitat G
Oncol Res; 2009; 17(11-12):565-70. PubMed ID: 19806787
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
4. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.
Vaishampayan U; Fontana J; Du W; Hussain M
Urology; 2002 Dec; 60(6):1050-4. PubMed ID: 12475668
[TBL] [Abstract][Full Text] [Related]
5. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
7. Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer.
Odrazka K; Vaculikova M; Petera J; Moravek P; Prosvic P; Zoul Z; Rydel L; Brodak M; Veselsky Z; Louda M; Simakova E
Int J Urol; 2003 Jul; 10(7):387-91. PubMed ID: 12823694
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer.
Kuzel TM; Kies MS; Wu N; Hsieh YC; Rademaker AW
Cancer Invest; 2002; 20(5-6):634-43. PubMed ID: 12197218
[TBL] [Abstract][Full Text] [Related]
14. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
Chiappino I; Destefanis P; Addeo A; Galetto A; Cucchiarale G; Munoz F; Zitella A; Ferrando U; Fontana D; Ricardi U; Tizzani A; Bertetto O
Am J Clin Oncol; 2007 Jun; 30(3):234-8. PubMed ID: 17551298
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Di Bonito M; Rivellini F; Carteni G; De Lucia L; Maiorino L; D'Aniello R; Frezza P; Lapenta L; Comella G
Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
[TBL] [Abstract][Full Text] [Related]
16. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.
Trivedi C; Redman B; Flaherty LE; Kucuk O; Du W; Heilbrun LK; Hussain M
Cancer; 2000 Jul; 89(2):431-6. PubMed ID: 10918176
[TBL] [Abstract][Full Text] [Related]
17. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.
Petrioli R; Paolelli L; Francini E; Manganelli A; Salvestrini F; Francini G
Urology; 2007 Jan; 69(1):142-6. PubMed ID: 17270637
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
Vaughn DJ; Brown AW; Harker WG; Huh S; Miller L; Rinaldi D; Kabbinavar F
Cancer; 2004 Feb; 100(4):746-50. PubMed ID: 14770430
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
20. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Friedland DM; Dakhil S; Hollen C; Gregurich MA; Asmar L
Cancer Invest; 2004; 22(3):374-82. PubMed ID: 15493358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
